Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesHelix BioPharma Corp

Helix BioPharma Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.77 USD 0.00(0%)
Last update at 2026-11-06T14:30:00Z
Market Cap
31.42M

Momentum Score

…

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.77
Low
0.77
High
52 Week Price Range
0.14
Low
0.16
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Helix BioPharma Corp is a small, clinical-stage biotechnology company focused on oncology and immunotherapy development, advancing early-stage drug candidates and platform technologies. Long-term growth drivers include clinical trial progress, regulatory milestones, strategic partnerships or licensing, and successful capital raises, which may benefit long-term value if programs show safety and efficacy.
Material risks include high clinical and regulatory failure probability, limited liquidity and reporting transparency as an OTC-listed small-cap, persistent financing and dilution risk, and uncertain commercial prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.77
Dividend Yield
2.09%
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
7.74
ROE
-1205.79%
Net Debt
-0.81M
ROCE
743.08%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Income before tax -6.29M -6.56M -9.57M -8.56M -7.53M
Minority interest - - 0.00M 0.59M 0.59M
Net income -6.29M -6.56M -8.04M -8.98M -7.53M
Selling general administrative 0.30M 0.59M 3.25M 2.72M 2.47M
Reconciled depreciation 0.01M 0.01M 0.20M 0.21M 0.12M
Ebit -6.28M -6.54M -9.61M -8.59M -7.49M
Ebitda -6.27M -6.53M -9.41M -8.38M -7.36M
Depreciation and amortization 0.01M 0.01M 0.20M 0.21M 0.12M
Operating income -6.28M -6.54M -9.61M -8.59M -7.49M
Other operating expenses 6.33M 6.04M 9.13M 8.62M 7.49M
Interest expense 0.01M 0.02M 0.01M 0.03M 0.00M
Interest income 0.05M 0.00M 0.00M 0.03M 0.00M
Net interest income 0.03M -0.01M -0.35M 0.00M 0.00M
Income tax expense 0.01M -0.48M -1.66M 0.45M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 6.33M 6.04M 9.13M 8.62M 7.49M
Total other income expense net 0.00M -0.51M -0.09M 0.06M -0.04M
Discontinued operations - - 1.54M -0.61M -0.72M
Net income from continuing ops -6.29M -6.56M -9.57M -8.56M -7.53M
Net income applicable to common shares - -6.56M -8.04M -8.98M -7.53M
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Total assets 1.03M 3.73M 4.07M 4.91M 0.94M
Intangible assets - - - - 0.00M
Other current assets - -0.00M - 0.15M -
Total liab 1.87M 3.41M 5.46M 1.93M 4.22M
Total stockholder equity -0.84M 0.32M -1.39M 2.39M -3.28M
Other current liab 1.38M 0.34M 0.38M 0.35M 1.06M
Common stock 152.07M 147.51M 139.66M 137.26M 129.53M
Capital stock 152.07M 147.51M 139.66M 137.26M 129.53M
Retained earnings -201.41M -195.12M -188.55M -180.52M -171.53M
Other assets - -0.00M - - -
Cash 0.81M 3.25M 3.56M 4.24M 0.21M
Total current liabilities 1.87M 3.41M 3.87M 1.93M 4.22M
Current deferred revenue - 0.34M - 0.30M 0.12M
Net debt -0.81M -0.78M 0.05M -4.08M -0.21M
Short term debt - 2.47M 2.03M 0.16M -
Short long term debt - 2.47M 2.03M - -
Short long term debt total - 2.47M 3.61M 0.16M -
Other stockholder equity 48.49M 47.92M 47.50M 45.65M 38.72M
Property plant equipment - 0.04M 0.05M 0.25M 0.25M
Total current assets 1.00M 3.69M 4.02M 4.66M 0.69M
Net tangible assets - 0.32M -1.39M 2.39M -3.28M
Net receivables 0.06M 0.28M 0.35M 0.18M 0.29M
Long term debt - - 1.58M - -
Inventory - 0.16M - - -
Accounts payable 0.49M 0.60M 1.47M 1.42M 3.04M
Non currrent assets other - 0.00M - - -
Non current assets total 0.03M 0.04M 0.05M 0.25M 0.25M
Capital lease obligations - - - 0.16M -
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Investments -0.01M 0.00M 2.02M 1.70M -0.00M
Change to liabilities - -0.87M 0.05M -1.54M 1.08M
Total cashflows from investing activities - - 2.02M 1.70M -0.00M
Net borrowings - - 3.00M -0.15M -0.15M
Total cash from financing activities 3.09M 6.21M 6.56M 13.10M 5.41M
Change to operating activities - -0.10M 0.07M -0.63M 0.31M
Net income -6.29M -6.56M -8.04M -8.56M -7.53M
Change in cash -2.44M -0.31M -0.67M 4.03M -0.16M
Begin period cash flow 3.25M 3.56M 4.24M 0.21M 0.37M
End period cash flow 0.81M 3.25M 3.56M 4.24M 0.21M
Total cash from operating activities -5.53M -6.51M -9.30M -10.83M -5.53M
Issuance of capital stock 4.15M 2.99M 3.56M 12.19M 5.41M
Depreciation 0.01M 0.01M 0.20M 0.21M 0.12M
Other cashflows from investing activities - - - - -0.00M
Change to inventory - - - - 0.31M
Change to account receivables 0.22M 0.07M -0.17M 0.06M 0.03M
Other cashflows from financing activities 1.00M 3.21M 3.16M 1.06M -0.00M
Change to netincome - 0.93M -1.41M 0.06M 0.50M
Capital expenditures 0.01M 0.00M 0.00M 0.02M 0.00M
Change in working capital 0.19M -0.89M -0.05M -2.11M 1.47M
Stock based compensation 0.57M 0.42M 0.66M 0.47M 0.36M
Other non cash items -0.01M 0.51M -2.07M -0.84M 0.04M
Free cash flow -5.54M -6.51M -9.30M -10.84M -5.54M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
HBPCF
Helix BioPharma Corp		 -
-%		 0.77 - - - 42.66 -5.65
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Helix BioPharma Corp

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

401 Bay Street, Toronto, ON, Canada, M5H 2Y4

905 841 2300

https://www.helixbiopharma.com

9

Name Title Year Born
Mr. Hatem Kawar M.B.A., MBA, P.Eng, P.Eng. Chief Financial Officer 1959
Dr. Gabrielle M. Siegers M.A., Ph.D. Head of R&D NA
Ms. Namrata Malhotra Corp. Sec. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…